Home > Pulmonology > ERS 2023 > Pulmonary Arterial Hypertension (PAH): Novel Developments > Women with pulmonary hypertension have better survival chances than men

Women with pulmonary hypertension have better survival chances than men

Presented by
Dr Anna Titz, University Hospital Zürich, Switzerland
Conference
ERS 2023
Doi
https://doi.org/10.55788/0da352e1
In patients with combined post- and pre-capillary pulmonary hypertension (CpcPH), the mortality risk was higher for men than for women. Also, having a mean pulmonary artery pressure (mPAP) above 46 mmHg was linked to a significantly lower probability of survival.

“The Swiss PH Registry is a collaboration between 13 Swiss hospitals that has been established in 1998, and includes patients with newly diagnosed pulmonary hypertension from 2000 onwards,” stated Dr Anna Titz (University Hospital Zürich, Switzerland) [1]. Registry data from 2001–2019 served as a basis for a retrospective analysis that assessed epidemiology and long-term outcomes of patients with CpcPH [1,2]. CpcPH was defined by a mean mPAP over 20 mmHg and a pulmonary vascular resistance (PVR) above 2 Wood units. The study comprised a Kaplan-Meier survival analysis and a Cox regression analysis that included baseline characteristics, risk assessment strata, 6-minute-walking test scores, and BNP/NT-proBNP levels. The study cohort consisted of 231 patients, among them 137 women. Further assessment of demographics observed a mean age of 65, a mean mPAP of 48 mmHg, and a mean PVR of 7.2 Wood units. “Surprisingly, our data shows that 47% of our cohort received PH-targeted medication,” Dr Titz emphasised, while mentioning the conflicting evidence that currently exists regarding these medication in patients with PH based on left heart disease.

The results demonstrated a statistically significant higher survival probability for women compared with men (P=0.011). One factor influencing survival was mPAP, as having an mPAP over 46 mmHg was linked to higher mortality (P=0.035). “We also stratified our patients according to the 4-strata risk assessment tool, by using the non-invasively assessed parameters: functional class, 6-minute walking test, and NT-proBNP,” Dr Titz informed. These results showed that high-risk patients in the 4-strata risk assessment have a lower survival probability than those with low/intermediate risk. These findings were also corroborated by the results of the Cox regression analysis, with significant hazard ratios of 0.58 for being female, 1.58 for mPAP >46 mmHg, and 2.44 for high-risk patients (see Figure). However, a significant influence on survival of age or pulmonary vascular resistance could not be established.

“In this patient cohort with combined post- and pre-capillary pulmonary hypertension, women and patients with a lower mPAP revealed a longer survival,” Dr Titz summarised.

Figure: Cox regression analysis: Women have a statistically significant higher survival probability [1]


  1. Titz A. Long-term outcome of patients with combined post- and precapillary pulmonary hypertension. Abstract 747, ERS 2023 Congress, 9–13 September, Milan, Italy.
  2. Titz A, et al. Eur Heart J Open. 2023 Jul 3;3(4):oead069.

Copyright ©2023 Medicom Medical Publishers



Posted on